Sun believes Caraco seizure will not hit US sales
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries is hoping that the recent seizure of drugs at its subsidiary Caraco's Michigan facilities will not affect sales of its products in the US, despite the large dent to its credibility. Sun's products, worth about $225 million in revenues, are distributed by Caraco in the US.